Prognostic and survival analyses of early-stage diffuse large B-cell lymphoma of Waldeyer′s ring
10.3760/cma.j.issn.1004-4221.2019.12.004
- VernacularTitle: 早期韦氏环弥漫大B细胞淋巴瘤预后分析
- Author:
Huan LI
1
;
Tao WU
;
Qiulin LIN
;
Jing ZHANG
;
Yunfei HU
;
Mengxiang CHEN
;
Yunhong HUANG
;
Bing LU
Author Information
1. Guizhou Medical University, Department of Oncology, The Affiliated Cancer Hospital of Guizhou Medical University, Department of Lymphoma, Guizhou Cancer Hospital, Guiyang 550001, China
- Publication Type:Journal Article
- Keywords:
Diffuse large B-cell lymphoma of Waldeyer′s ring/targeted therapy;
Diffuse large B-cell lymphoma of Waldeyer′s ring/radiotherapy;
Diffuse large B-cell lymphoma of Waldeyer′s ring/chemotherapy;
Prognosis
- From:
Chinese Journal of Radiation Oncology
2019;28(12):896-900
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the clinical efficacy and prognostic factors of patients with early-stage diffuse large B-cell lymphoma of Waldeyer′s ring (WR-DLBCL) treated with CHOP-based chemotherapy.
Methods:A total of 137 patients diagnosed with WR-DLBCL admitted to our hospitalfrom 2006 to 2018 were enrolled, including 22 patients with stage Ⅰ and 115 patients with stage Ⅱ WR-DLBCL. All patients received CHOP-based chemotherapy, of whom 62 receiving rituximab and 87 receiving involved-field radiotherapy. The overall survival (OS), progression-free survival (PFS) and local recurrence-free survival (LRRFS) were calculated by Kaplan-Meier method. Log-rank test, was conducted for univariate analysis and Cox’s regression model was performed for multivariate analysis.
Results:The 5-year OS, PFS, and LRFFS in the whole group were 78.6%, 69.5% and 83.2%, and 87.5%, 80.2%, 90.9% in the comprehensive treatment group, and 64.2%, 53.6% 72.9% in the chemotherapy group, respectively. Univariate analysis showed that lactate dehydrogenase (LDH), international prognostic index score, large mass, rituximab, chemotherapy cycle and comprehensive treatment were the prognostic factors of OS and PFS. In addition, LDH, large mass and comprehensive treatment were the prognostic factors associated with LRFFS. Multivariate analysis demonstrated that LDH, comprehensive treatment mode and rituximab were the prognostic factors of OS. LDH and comprehensive treatment mode were the prognostic factors associated with PFS. LDH was a prognostic factor of LRFFS.
Conclusion:Patients with early-stage WR-BLBCL obtain excellent clinical prognosis. In the era of rituximab treatment, chemotherapy combined with radiotherapy remains an efficacious treatment of early-stage WR-BLBCL.
